Frank Osterkamp

1.0k total citations · 1 hit paper
21 papers, 584 citations indexed

About

Frank Osterkamp is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Cellular and Molecular Neuroscience. According to data from OpenAlex, Frank Osterkamp has authored 21 papers receiving a total of 584 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Radiology, Nuclear Medicine and Imaging and 7 papers in Cellular and Molecular Neuroscience. Recurrent topics in Frank Osterkamp's work include Peptidase Inhibition and Analysis (9 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Neuropeptides and Animal Physiology (7 papers). Frank Osterkamp is often cited by papers focused on Peptidase Inhibition and Analysis (9 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Neuropeptides and Animal Physiology (7 papers). Frank Osterkamp collaborates with scholars based in Germany, United States and Thailand. Frank Osterkamp's co-authors include Christiane Smerling, Ulrich Reineke, Richard P. Baum, Harshad Kulkarni, Aviral Singh, Aileen Hoehne, Christiane Schuchardt, Dirk Zboralski, Maythinee Chantadisai and Dirk Müeller and has published in prestigious journals such as Blood, Cancer Research and Chemical Communications.

In The Last Decade

Frank Osterkamp

21 papers receiving 578 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷Lu-FAP-2286: First-in-Humans Results

2021 210 citations Richard P. Baum, Christiane Schuchardt et al. Journal of Nuclear Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frank Osterkamp Germany	12	361	214	177	124	112	21	584
Jianyang Fang China	12	383 1.1×	200 0.9×	100 0.6×	106 0.9×	144 1.3×	34	522
Simone U. Dalm Netherlands	19	549 1.5×	496 2.3×	151 0.9×	119 1.0×	50 0.4×	42	967
Peter Conti United States	9	147 0.4×	232 1.1×	179 1.0×	15 0.1×	67 0.6×	25	536
Thorsten Poethko Germany	16	266 0.7×	847 4.0×	247 1.4×	20 0.2×	56 0.5×	21	1.2k
Ingrid J.G. Burvenich Australia	14	236 0.7×	231 1.1×	288 1.6×	32 0.3×	24 0.2×	49	669
Do Hyun Nam South Korea	14	175 0.5×	30 0.1×	193 1.1×	26 0.2×	72 0.6×	34	725
Sonal Varma Canada	12	106 0.3×	87 0.4×	193 1.1×	17 0.1×	55 0.5×	32	456
Sara S. Rinne Sweden	19	351 1.0×	541 2.5×	202 1.1×	42 0.3×	13 0.1×	44	676
Maria‐Luisa Tamma Switzerland	12	356 1.0×	379 1.8×	117 0.7×	107 0.9×	23 0.2×	14	641
Jyoti Roy United States	11	136 0.4×	90 0.4×	130 0.7×	31 0.3×	54 0.5×	18	360

Countries citing papers authored by Frank Osterkamp

Since Specialization

Citations

This map shows the geographic impact of Frank Osterkamp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Osterkamp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Osterkamp more than expected).

Fields of papers citing papers by Frank Osterkamp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Osterkamp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Osterkamp. The network helps show where Frank Osterkamp may publish in the future.

Co-authorship network of co-authors of Frank Osterkamp

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Osterkamp. A scholar is included among the top collaborators of Frank Osterkamp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Osterkamp. Frank Osterkamp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wiedemann, Norbert, Aileen Hoehne, Frank Osterkamp, et al.. (2024). Preclinical Characterization of DPI-4452: A⁶⁸Ga/¹⁷⁷Lu Theranostic Ligand for Carbonic Anhydrase IX. Journal of Nuclear Medicine. 65(5). 761–767. 16 indexed citations

Hoehne, Aileen, et al.. (2023). 3BP-3940, a highly potent FAP-targeting peptide for theranostics - production, validation and first in human experience with Ga-68 and Lu-177. iScience. 26(12). 108541–108541. 11 indexed citations

Zboralski, Dirk, Frank Osterkamp, Aileen Hoehne, et al.. (2023). Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition. European Journal of Nuclear Medicine and Molecular Imaging. 50(9). 2621–2635. 27 indexed citations

Zboralski, Dirk, Aileen Hoehne, Matthias Paschke, et al.. (2022). Abstract 3317: Comparative biodistribution and radiotherapeutic efficacy of the fibroblast activation protein (FAP)-targeting agents FAP-2286 and FAPI-46. Cancer Research. 82(12_Supplement). 3317–3317. 4 indexed citations

Baum, Richard P., Christiane Schuchardt, Aviral Singh, et al.. (2021). Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷Lu-FAP-2286: First-in-Humans Results. Journal of Nuclear Medicine. 63(3). 415–423. 210 indexed citations breakdown →

Kwan, Tanya T., Minh Nguyen, Dirk Zboralski, et al.. (2021). Abstract LBA032: Pan-cancer analysis of fibroblast activation protein alpha (FAP) expression to guide tumor selection for the peptide-targeted radionuclide therapy FAP-2286. Molecular Cancer Therapeutics. 20(12_Supplement). LBA032–LBA032. 4 indexed citations

Zboralski, Dirk, Frank Osterkamp, Andrew D. Simmons, et al.. (2020). 571P Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP). Annals of Oncology. 31. S488–S488. 14 indexed citations

Baum, Richard P., Maythinee Chantadisai, Christiane Smerling, et al.. (2020). Peptide-Targeted Radionuclide Therapy (PTRT) using Lu-177 FAP-2286 in Diverse Adenocarcinomas: Feasibility, Biodistribution and Preliminary Dosimetry in a First-in-human study. 61. 633–633. 4 indexed citations

Baum, Richard P., Aviral Singh, Christiane Schuchardt, et al.. (2017). ¹⁷⁷Lu-3BP-227 for Neurotensin Receptor 1–Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results. Journal of Nuclear Medicine. 59(5). 809–814. 58 indexed citations

10.

Goldschmidt, Jürgen, Franziska Stöber, Mercedes Noriega, et al.. (2017). Proof of Therapeutic Efficacy of a¹⁷⁷Lu-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model. Journal of Nuclear Medicine. 58(6). 936–941. 40 indexed citations

11.

Goldschmidt, Jürgen, Oliver S. Großer, Frank Osterkamp, et al.. (2016). Comparative Evaluation of the Biodistribution Profiles of a Series of Nonpeptidic Neurotensin Receptor-1 Antagonists Reveals a Promising Candidate for Theranostic Applications. Journal of Nuclear Medicine. 57(7). 1120–1123. 30 indexed citations

12.

Kulkarni, Harshad, Christiane Schuchardt, Stefan Wiessalla, et al.. (2015). Radiopeptide Therapy using Lu-177 3BP-227 in a Patient with Pancreatic Adenocarcinoma. 56. 1235–1235. 2 indexed citations

13.

Zischinsky, Gunther, et al.. (2009). SAR of N-phenyl piperidine based oral integrin α5β1 antagonists. Bioorganic & Medicinal Chemistry Letters. 20(1). 65–68. 5 indexed citations

14.

Zischinsky, Gunther, et al.. (2009). Discovery of orally available integrin α5β1 antagonists. Bioorganic & Medicinal Chemistry Letters. 20(1). 380–382. 6 indexed citations

15.

Stragies, Roland, et al.. (2007). Design and Synthesis of a New Class of Selective Integrin α5β1 Antagonists. Journal of Medicinal Chemistry. 50(16). 3786–3794. 57 indexed citations

16.

Christner, Claudia, et al.. (2004). Identification of hPin1 inhibitors that induce apoptosis in a mammalian Ras transformed cell line. Chemical Communications. 516–516. 26 indexed citations

17.

Preißner, Robert, et al.. (2001). Matching organic libraries with protein-substructures. Journal of Computer-Aided Molecular Design. 15(9). 811–817. 10 indexed citations

18.

Osterkamp, Frank, et al.. (2000). Synthesis and Biological Evaluation of Integrin Antagonists Containingtrans- andcis-2,5-Disubstituted THF Rings. Chemistry - A European Journal. 6(4). 666–683. 25 indexed citations

19.

Schrey, Anna K., et al.. (1999). Synthesis of Enantiomerically Pure Amino Acids Containing 2,5-Disubstituted THF Rings in the Molecular Backbone. European Journal of Organic Chemistry. 1999(11). 2977–2990. 20 indexed citations

20.

Osterkamp, Frank, et al.. (1999). Synthesis and biological evaluation of dianhydrohexitol integrin antagonists. Tetrahedron. 55(35). 10713–10734. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact